RIO DE JANEIRO, BRAZIL - Using blood plasma from COVID-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released on Tuesday, November 24th, from a clinical trial in Argentina.
The therapy know as convalescent plasma, which delivers antibodies from COVID-19 survivors to infected people, did not significantly improve patients’ health status or reduce their risk of dying from the disease any better than a placebo, the study published in The New England Journal of Medicine found.
Despite limited evidence of its efficacy, convalescent plasma, which U.S. President Donald . . .